While promising, be VERY skeptical about efficacy claims of these early stage research drugs.

Tons of drugs in the pipeline that goes after these promising receptor targets. PD-1/PD-L1, CD47, CD40 (as mentioned in the article) etc. Keytruda (PD-1) is an incredible success both clinically and commercially, but there are many many other drugs buried in the clinical trial cemetery that initially showed promising results.

Medicine is really hard.